The serum digoxin concentration: Ten questions to ask

American Family Physician

Volumn 56, Issue 2, 1997, Pages 495-503

  Cauffield, Jacintha S ^a   Gums, John G ^a   Grauer, Ken ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CISAPRIDE; COLESTIPOL; COLESTYRAMINE; DIGOXIN; DILTIAZEM; IBUPROFEN; INDOMETACIN; KAOLIN PECTIN; METOCLOPRAMIDE; PROPANTHELINE BROMIDE; QUINIDINE; QUINIDINE GLUCONATE; QUINIDINE POLYGALACTURONATE; QUINIDINE SULFATE; SPIRONOLACTONE; SUCRALFATE; VERAPAMIL;

DIGOXIN BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG HALF LIFE; ELIXIR; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; ORAL DRUG ADMINISTRATION; REVIEW; TABLET;

ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; CARDIOTONIC AGENTS; DIGOXIN; HUMANS;

EID: 0030854502     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7.
2. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22:955-62.
3. Howanitz PJ, Steindel SJ. Digoxin therapeutic drug monitoring practices. A College of American Pathologists Q-Probes study of 666 institutions and 18,679 toxic levels. Arch Pathol Lab Med 1993; 117:684-90.
4. Reuning RH, Geraets DR, Rocci ML Jr, Vlasses PH. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3d ed. Vancouver, Wash.: Applied Therapeutics, 1992;20:1-48.
5. Mooradian AD. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988;15:165-79.
6. Digoxin. In: AHFS drug information 96. Bethesda, Md.: American Society of Health-System Pharmacists, 1996:1088-98.
7. Lewis RP. Clinical use of serum digoxin concentrations. Am J Cardiol 1992;69:97-106.
8. Dobbs RJ, O'Neill CJ, Deshmukh AA, Nicholson PW, Dobbs SM. Serum concentration monitoring of cardiac glycosides. How helpful is it for adjusting dosage regimens? Clin Pharmacokinet 1991; 20:175-93.
9. Geraets DR, Kienzle MG. Atrial fibrillation and atrial flutter. Clin Pharm 1993;12:721-35.
10. Grauer K, Cavallaro D, eds. ACLS: rapid review and case scenarios. St. Louis: Mosby, 1996.
11. Grauer K, Curry RW Jr, Robinson JD. Prediction of serum concentrations of digoxin in a family practice center. J Fam Pract 1982;15:1081-6.
12. Hooymans PM, Merkus FW. Current status of cardiac glycoside drug interactions. Clin Pharm 1985;4:404-13.
13. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15:227-44.
14. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-94.
15. Bussey HI. The influence of quinidine and other agents on digitalis glycosides. Am Heart J 1982; 104(2 Pt 1):289-302.
16. Bussey HI. Update on the influence of quinidine and other agents on digitalis glycosides. Am Heart J 1984;107:143-6.
17. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Pedersen KK. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol 1982;22:123-7.
18. Schwartz JB, Keefe D, Kates RE, Kirsten E, Harrison DC. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 1982;65:1163-70.
19. Moysey JO, Jaggarao NS, Grundy EN, Chamberlain DA. Amiodarone increases plasma digoxin concentrations. Br Med J (Clin Res) 1981;282:272.
20. Hedman A, Angelin B, Arvidsson A, Dahlqvist R. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol 1992;42:481-5.
21. Pleasants RA, Williams DM, Porter RS, Gadsden RH Sr. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays. Ther Drug Monit 1989;11:200-4.
22. Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration. DICP 1991;25:745-6.